Smallpox/Mpox vaccine
Commercial- Indications
- Smallpox, Mpox
Company intelligence / Profile preview
BN ImmunoTherapeutics developed recombinant poxvirus-based therapeutic vaccines for oncology indications. Its lead programs included a HER2-targeted breast cancer vaccine and a PSA-targeted prostate cancer vaccine. Both advanced into early-stage clinical trials to assess safety, tolerability, immune response generation, and preliminary efficacy signals. No recent updates suggest ongoing independent activity.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BN ImmunoTherapeutics.